Literature DB >> 26966418

De-escalation of bone-targeted agents for metastatic prostate cancer.

Brian Younho Hong1, Mohammed F K Ibrahim2, Ricardo Fernandes2, Sasha Mazzarello3, Brian Hutton4, Risa Shorr5, Mark Clemons6.   

Abstract

Entities:  

Year:  2016        PMID： 26966418      PMCID： PMC4754074          DOI： 10.3747/co.23.2913

Source DB:  PubMed          Journal:  Curr Oncol        ISSN： 1198-0052            Impact factor:   3.677


× No keyword cloud information.
  4 in total

1.  Efficacy of pamidronate in reducing skeletal complications in patients with breast cancer and lytic bone metastases. Protocol 19 Aredia Breast Cancer Study Group.

Authors:  G N Hortobagyi; R L Theriault; L Porter; D Blayney; A Lipton; C Sinoff; H Wheeler; J F Simeone; J Seaman; R D Knight
Journal:  N Engl J Med       Date:  1996-12-12       Impact factor: 91.245

Review 2.  Should de-escalation of bone-targeting agents be standard of care for patients with bone metastases from breast cancer? A systematic review and meta-analysis.

Authors:  M F K Ibrahim; S Mazzarello; R Shorr; L Vandermeer; C Jacobs; J Hilton; B Hutton; M Clemons
Journal:  Ann Oncol       Date:  2015-06-28       Impact factor: 32.976

Review 3.  Bone markers and their prognostic value in metastatic bone disease: clinical evidence and future directions.

Authors:  Robert Coleman; Janet Brown; Evangelos Terpos; Allan Lipton; Matthew R Smith; Richard Cook; Pierre Major
Journal:  Cancer Treat Rev       Date:  2008-06-24       Impact factor: 12.111

4.  Denosumab treatment of prostate cancer with bone metastases and increased urine N-telopeptide levels after therapy with intravenous bisphosphonates: results of a randomized phase II trial.

Authors:  Karim Fizazi; Linda Bosserman; Guozhi Gao; Tomas Skacel; Richard Markus
Journal:  J Urol       Date:  2009-06-13       Impact factor: 7.450
  4 in total
  4 in total

Review 1.  Prostate cancer induced bone pain: pathobiology, current treatments and pain responses from recent clinical trials.

Authors:  A E Smith; A Muralidharan; M T Smith
Journal:  Discov Oncol       Date:  2022-10-18

2.  Symptomatic skeletal-related events in patients receiving longer term bone-modifying agents for bone metastases from breast and castration resistant prostate cancers.

Authors:  Mashari Alzahrani; Carol Stober; Michelle Liu; Arif Awan; Terry L Ng; Gregory Pond; Bader Alshamsan; Lisa Vandermeer; Mark Clemons
Journal:  Support Care Cancer       Date:  2022-01-21       Impact factor: 3.603

3.  Two-year results of a randomised trial comparing 4- versus 12-weekly bone-targeted agent use in patients with bone metastases from breast or castration-resistant prostate cancer.

Authors:  Mark Clemons; Michelle Liu; Carol Stober; Gregory Pond; Mashari Jemaan Alzahrani; Michael Ong; Scott Ernst; Christopher Booth; Mihaela Mates; Anil Abraham Joy; Olexiy Aseyev; Phillip Blanchette; Lisa Vandermeer; Megan Tu; Kednapa Thavorn; Dean Fergusson
Journal:  J Bone Oncol       Date:  2021-09-02       Impact factor: 4.072

4.  A randomised trial of 4- versus 12-weekly administration of bone-targeted agents in patients with bone metastases from breast or castration-resistant prostate cancer.

Authors:  Mark Clemons; Michael Ong; Carol Stober; Scott Ernst; Christopher Booth; Christina Canil; Mihaela Mates; Andrew Robinson; Phillip Blanchette; Anil Abraham Joy; John Hilton; Olexiy Aseyev; Gregory Pond; Ahwon Jeong; Brian Hutton; Sasha Mazzarello; Lisa Vandermeer; Igal Kushnir; Dean Fergusson
Journal:  Eur J Cancer       Date:  2020-10-03       Impact factor: 9.162
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.